If you have been reading about MC4R and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
PT-141 initiates cellular signaling by binding to specific subtypes within the melanocortin receptor family. These receptors belong to the G protein-coupled receptor superfamily, and activation raises intracellular cyclic adenosine monophosphate levels. This cascade ultimately influences neuronal circuits in the central nervous system that are associated with sexual desire and arousal. Research indicates the compound's action concentrates in hypothalamic regions rather than peripheral tissues, which helps explain some observed pharmacological features. The selectivity of receptor binding underlies its functional differences.
Compared with the related compound melanotan II, PT-141 shows markedly weaker activation of receptors tied to pigmentation. This difference stems from subtle structural variations that alter affinity distribution across receptor subtypes. Investigators propose that such selectivity produces a different side effect profile in specific applications. However, downstream consequences of prolonged receptor activation remain uncertain in the literature. Published studies do not fully agree on the duration of signaling pathway activity and the mechanisms of desensitization.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
| Property | Value | Notes |
|---|---|---|
| Primary target | Melanocortin receptors | Mainly the MC4R subtype |
| Route of administration | Injection | Typically subcutaneous |
| Time to peak | About 60 minutes | After subcutaneous dosing |
| Elimination half-life | Roughly 2 to 3 hours | Values vary across reports |
| Metabolic pathway | Peptidase hydrolysis | Cleared by the kidneys |
The peptide contains seven amino acids arranged in a ring, closed by a lactam bridge between a side-chain acid and an amine. This cyclic constraint holds the backbone in a defined conformation and increases resistance to enzymatic breakdown relative to linear analogs. N-terminal acetylation and a C-terminal amide further protect the molecule from exopeptidases. The result is a compound with a comparatively long circulation time for a small peptide. Structural modification of the bridge alters receptor affinity, which is one reason analogs in this family differ in their subtype preferences.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Published studies differ in design, population and endpoint definition, so results are not always directly comparable across reports. Some trials used patient-reported measures of desire and distress, while others tracked physiological or behavioural outcomes. Questions that remain open include the durability of effects beyond short follow-up periods, the frequency of transient blood pressure elevation observed after administration, and whether a subtype-selective analogue could separate central effects from pigmentation-related activity. These points are usually framed as unresolved rather than settled in review literature.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
In vitro (meaning in glass, or in the glass) studies are performed with cells or biological molecules outside their normal biological context. Colloquially called "test-tube experiments", these studies in biology and its subdisciplines are traditionally done in labware such as test tubes, flasks, Petri dishes, and microtiter plates. Studies conducted using components of an organism that have been isolated from their usual biological surroundings permit a more detailed or more convenient analysis than can be done with whole organisms; however, results obtained from in vitro experiments may not fully or accurately predict the effects on a whole organism. In contrast to in vitro experiments, in vivo studies are those conducted in living organisms, including humans, known as clinical trials, and whole plants.
== Research == A 2016 review found that reserpine reduced systolic blood pressure (SBP) by about 8 mmHg compared to placebo, and may be as effective at reducing SBP as other front-line hypertensive drugs, although more research is needed to determine a dose-specific safety profile.
== Preparation == The highly basic character of caricain makes it relatively easy to separate from the other papaya cysteine endopeptidases in cation-exchange chromatography of preparations of commercially available papaya latex. A sodium acetate gradient, pH 5.0, was first used successfully by Robinson and has since been adopted by others. Caricain is found in the latest-eluting protein peak. Due to the charge heterogeneity of caricain the peak may not be symmetrical, but this does not necessarily indicate the presence of contaminants. Covalent chromatography on thiol-Sepharose allows isolation of fully active caricain from the material obtained by cation exchange.
Sources: en.wikipedia.org
=== Background === The name CosMc originated as a McDonaldland character, appearing in McDonald's advertisements from 1986 to 1992. CosMc is an extraterrestrial who "craves McDonald's food." The character occasionally came to steal food for his planet, CosMcland. It also spoke in a mixture of robot-esque sounds and normal speech. In 2023, McDonald's started focusing more on its classic mascots and the Grimace Birthday Meal became a viral Internet phenomenon. The specialty coffee-selling business had been growing, which McDonald's CEO Chris Kempczinski described as an "attractive and fast growing category". CNN described CosMc's as McDonald's "answer to Starbucks."
Alteration of the viral envelope Structural alteration Alteration of viral markers or Alteration of the viral genome The exact mechanisms, for example of iodine (PVP-I), are still not clear, but it is targeting the bacterial protein synthesis due to disruption of electron transport, DNA denaturation or disruptive effects on the virus membrane.
== Discovery == Islets of Langerhans were first discussed by Paul Langerhans in his medical thesis in 1869. This same year, Édouard Laguesse named them after Langerhans. At first, there was a lot of controversy about what the Islets were made of and what they did. It appeared that all of the cells were the same within the Islet, but were histologically distinct from acini cells. Laguesse discovered that the cells within the Islets of Langerhans contained granules that distinguished them from acini cells. He also determined that these granules were products of the metabolism of the cells in which they were contained. Michael Lane was the one to discover that alpha cells were histologically different than beta cells in 1907. Before the function of alpha cells was discovered, the function of their metabolic product, glucagon, was discovered. The discovery of the function of glucagon coincides with the discovery of the function of insulin. In 1921, Banting and Best were testing pancreatic extracts in dogs that had had their pancreas removed. They discovered that "insulin-induced hypoglycemia was preceded by a transient, rather mild hyperglycemia..." Murlin is credited with the discovery of glucagon because in 1923 they suggested that the early hyperglycemic effect observed by Banting and Best was due to "a contaminant with glucogenic properties that they also proposed to call 'glucagon,' or the mobilizer of glucose". In 1948, Sutherland and de Duve established that alpha cells in the pancreas were the source of glucagon.
De novo gene birth is the process by which new genes evolve from non-coding DNA. De novo genes represent a subset of novel genes, and may be protein-coding or instead act as RNA genes. The processes that govern de novo gene birth are not well understood, although several models exist that describe possible mechanisms by which de novo gene birth may occur. Ancient de novo gene birth events are difficult to detect. Most studies of de novo genes to date have thus focused on young genes, typically taxonomically restricted genes (TRGs) that are present in a single species or lineage, including so-called orphan genes, defined as genes that lack any identifiable homolog. Not all orphan genes arise de novo, but rather through fairly well characterized mechanisms such as gene duplication (including retroposition) or horizontal gene transfer followed by sequence divergence, or by gene fission/fusion. Although de novo gene birth was once viewed as a highly unlikely occurrence, thousands of examples have now been described, and some researchers speculate that de novo gene birth could play a major role in evolutionary innovation, morphological specification, and adaptation, probably promoted by their low level of pleiotropy. Conversely, criticism of the methodology and interpretation used to identify de novo gene candidates has appeared in the literature, including arguments that some reported cases may reflect artefacts of homology detection and annotation rather than genuine novelty.
Sources: en.wikipedia.org
Three-quarters of sickle cell cases occur in Africa. A World Health Organization report dated 2006 estimated that around 2% of newborns in Nigeria are affected by sickle cell anaemia, giving a total of 150,000 affected children born every year in Nigeria alone. The carrier frequency ranges between 10 and 40% across equatorial Africa, decreasing to 1–2% on the North African coast and <1% in South Africa. In the West African countries of Ghana and Nigeria, the frequencies can vary from 15 to 30%. In Nigeria, 24% of the population carries the gene, and 20 per 1,000 newborns are born with the disease, or 150,000 annually. Uganda has the fifth-highest sickle cell disease burden in Africa. One study indicates that 20,000 babies per year, or 0.7% of the total, are born with sickle cell disease, and 13.3% carry the trait. In Uganda, carrier frequency of the trait varies strongly across tribal lines: among the Baamba, it reaches 45%.
John Cox Stevens (1803), founder and first commodore of the New York Yacht Club, won the first America's Cup trophy in 1851 Reginald Sayre (1881), orthopedic surgeon and Olympic sport shooter Charles Sands (1887), athlete who won the gold medal in Golf at the 1900 Summer Olympics Oliver Campbell (1891), tennis player; youngest male winner of the US Open Singles title 1890–1990 Charles Townsend (1893), first Olympic fencer from the Ivy League; silver medalist in the 1904 Summer Olympics Gustavus Town Kirby (1895), president of the United States Olympic Committee 1920–1924, and Amateur Athletic Union 1911–1913 Leo Fishel (1899), first Jewish pitcher in Major League Baseball Harold Weekes (1903), football player for the Columbia Lions, member of the College Football Hall of Fame Harry A. Fisher (1905), basketball coach for Columbia, United States Military Academy, St. John's; member of the Basketball Hall of Fame Robert LeRoy (1905), two-time silver medalist in the 1904 Summer Olympics Eddie Collins (1907), baseball player for the Chicago White Sox and member of the Baseball Hall of Fame Marcus Hurley (1908), cyclist who won four gold medals in Cycling at the 1904 Summer Olympics Jay Gould II* (1911), real tennis player, Olympic gold medalist in 1908 and world champion 1914–1916; great-grandson of financier Jay Gould Ted Kiendl (1911), National Basketball Player of the Year in 1911; corporate lawyer, argued Erie Railroad Co. v.
== United Kingdom == The Public Health Laboratory Service (PHLS) was established as part of the National Health Service in 1946. An Emergency Public Health Laboratory Service was established in 1940 as a response to the threat of bacteriological warfare. There was originally a central laboratory at Colindale and a network of regional and local laboratories. By 1955 there were about 1000 staff. These laboratories were primarily preventive with an epidemiological focus. They were, however, in some places located with hospital laboratories which had a diagnostic focus. The PHLS was replaced by the Health Protection Agency in 2003; the HPA was disbanded and in its stead was constituted Public Health England, which later became the UK Health Security Agency in 2021.
== Signs and symptoms == Opiate overdose symptoms and signs can be referred to as the "opioid toxidrome triad": decreased level of consciousness, pinpoint pupils, and respiratory depression. Other signs and symptoms include seizures and muscle spasms. Sometimes, an opiate overdose can lead to such a decreased level of consciousness that the person will not wake up. Because of their effect on the part of the brain that regulates breathing, opioids can cause very slow or stopped breathing during overdoses, leading to hypoxia or death if left untreated. Hypoxia is typically caused by respiratory depression. The brain uses oxygen to regulate the homeostasis of the body. In animal studies, it was found that opioids act on specific regions of the central nervous system associated with respiratory regulation, including the medulla and pons. During cerebral hypoxia, the brain lacks sufficient oxygen supply. Prolonged lack of oxygenation from respiratory depression can lead to detrimental damage to the brain and spinal cord and can leave the person unable to walk or function normally, even if treatment with naloxone is given. Alcohol also causes respiratory depression and, therefore, when taken with opioids, can increase the risk of respiratory depression and death. In young children, opioid overdose may not be apparent right away. This is due to absorption, distribution, and metabolism differences between young children and adults and the higher amount of opioid ingestion per kilogram of body weight.
For comparison, other antidepressants, including fluoxetine, paroxetine, duloxetine, vilazodone, adjunctive aripiprazole, olanzapine/fluoxetine, and extended-release quetiapine, have NNTs ranging from 6 to 8 in terms of depression response and 7 to 14 in terms of depression remission. On the basis of these results, it was concluded that transdermal selegiline has similar effectiveness to other antidepressants. NNTs are measures of effect size and indicate how many individuals would need to be treated in order to encounter one additional outcome of interest. Lower NNTs are better, and NNTs corresponding to Cohen's d effect sizes have been defined as 2.3 for a large effect (d = 0.8), 3.6 for a medium effect (d = 0.5), and 8.9 for a small effect (d = 0.2). The effectiveness of transdermal selegiline for depression relative to side effects and discontinuation was considered to be favorable. While several large regulatory clinical trials of transdermal selegiline versus placebo for depression have been conducted, there is a lack of trials comparing selegiline to other antidepressants. Although multiple doses of transdermal selegiline were assessed, a dose–response relationship for depression was never established. Transdermal selegiline has shown similar clinical effectiveness in the treatment of atypical depression relative to typical depression and in the treatment of anxious depression relative to non-anxious depression.
Sources: en.wikipedia.org
It primarily activates specific subtypes in the melanocortin receptor family. These receptors are G protein-coupled and mediate signaling mainly within the central nervous system.
It activates pigmentation-related receptors more weakly. This selectivity is thought to alter its side effect profile.
Injection is the most common route. Nasal administration has been studied as well, though absorption varies considerably.
It belongs to the melanocortin receptor agonist family of peptides. Its cyclic structure distinguishes it from linear peptides and shapes its receptor binding profile.